20 clinical trials found.
-
An Open-Label Randomized Phase II Study of Combining Osimertinib with and without Ramucirumab in TKI-na ve EGFR-mutant Locally Advanced or Metastatic NSCLC
The purpose of this study is to find out whether the addition of ramucirumab to osimertinib is better at controlling EGFR lung cancer than just ...Phase
TRIAL ROLE: Sub Investigator
-
A Phase 1/2 Open-Label Multi-Center First-in-Human Study of the Safety Tolerability Pharmacokinetics and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK ROS1 or NTRK1-3 Rearrangements (TRIDENT-1)
The purpose of this Phase 1/2 research study is to test the effects of an investigational study drug called repotrectinib for the possible treatment ...Phase
TRIAL ROLE: Sub Investigator
-
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation
The purpose of this study is to test the safety, tolerability, and effectiveness of MRTX849 (called “the study drug” from now on) for advanced cancers ...Phase
TRIAL ROLE: Sub Investigator
-
A Phase 1 First-in-Human Open-Label Dose Escalation Study of JNJ-61186372 a Human Bispecific EGFR and cMet Antibody in Subjects with Advanced Non-Small Cell Lung Cancer
If you have been diagnosed with advanced, metastatic, non-small cell lung cancer (NSCLC), you may qualify for this study. The main goal of this study ...Phase
TRIAL ROLE: Sub Investigator
-
A Phase 1 Open-Label Dose-Escalation and Cohort Expansion First-in-Human Study of the Safety Tolerability Activity and Pharmacokinetics of REGN3767 (anti-LAG-3 mAb) Administered Alone or in Combination with REGN2810 (anti-PD-1 mAb) in Patients with Ad
If you have been diagnosed with advanced malignancies, an advanced form of cancer, you may be qualified to participate in this Phase I study evaluating ...Phase
TRIAL ROLE: Sub Investigator
-
MULTICENTER PHASE II NEOADJUVANT AND ADJUVANT STUDY OF ALECTINIB ENTRECTINIB OR VEMURAFENIB PLUS COBIMETINIB IN PATIENTS WITH STAGES I-III NON-SMALL CELL LUNG CANCER WITH ALK ROS1 NTRK OR BRAF V600E MOLECULAR ALTERATIONS
The purpose of the trial is to determine the efficacy and safety of drugs in patients with untreated non-small cell lung cancer (NSCLC) tumors. In ...Phase
TRIAL ROLE: Sub Investigator
-
Phase 1/1b Study to Evaluate the Safety & PK of JNJ-73841937 a Third Generation EGFR-TKI as Monotherapy or in Combinations With JNJ-61186372 a Human Bispecific EGFR and cMet Antibody in Participants With Advanced NSCLC
The purpose of the study is to determine the safety and tolerability of JNJ-73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations With ...Phase
TRIAL ROLE: Sub Investigator
-
A Phase 2 Umbrella Study with Rolling Arms of Investigational Agents with either Pembrolizumab in Combination with Chemotherapy or with Pembrolizumab Alone in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
The purpose of the study is to determine how well different drugs work in a single type of cancer for patients with advanced NSCLC. This ...Phase
TRIAL ROLE: Sub Investigator
-
A Randomized Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy Compared with Carboplatin-Pemetrexed in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
The purpose of the study is to demonstrate the improved efficacy of combining amivantamab with standard of care carboplatin-pemetrexed chemotherapy compared with carboplatin-pemetrexed chemotherapy in ...Phase
TRIAL ROLE: Sub Investigator
-
A Phase 3 Randomized Double-Blind Placebo-Controlled Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease has Remained Stable or Responded to First-Line Platinum-Based Chemotherapy with Pembrolizumab for Stage IIIB or IV Non-Small Cell Lung Cancer
The purpose of the study is to evaluate niraparib plus pembrolizumab versus placebo plus pembrolizumab in participants with advanced or metastatic nonsmall cell lung cancer ...Phase
TRIAL ROLE: Sub Investigator
